# EDGAR Filing Document

**Accession Number:** 0001473579
**File Stem:** 0001213900-23-005152
**Filing Date:** 2023-1
**Character Count:** 16535
**Document Hash:** 65b3291e5c712322ab28c62da1dd5301
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-005152.hdr.sgml**: 20230125

**ACCESSION NUMBER**: 0001213900-23-005152

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20230119

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230125

**DATE AS OF CHANGE**: 20230125

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NANOMIX Corp
- **CENTRAL INDEX KEY:** 0001473579
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 270801073
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54586
- **FILM NUMBER:** 23552928

**BUSINESS ADDRESS:**
- **STREET 1:** 354 MERRIMACK STREET
- **STREET 2:** #4
- **CITY:** LAWRENCE
- **STATE:** MA
- **ZIP:** 01843
- **BUSINESS PHONE:** (603) 935-9799

**MAIL ADDRESS:**
- **STREET 1:** 354 MERRIMACK STREET
- **STREET 2:** #4
- **CITY:** LAWRENCE
- **STATE:** MA
- **ZIP:** 01843

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Boston Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20101123

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AVANYX Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20091001

?xml version="1.0" encoding="utf-8"?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 19, 2023**

**<u>NANOMIX CORPORATION</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-54586** | **27-0801073** |
| (State or other jurisdiction | (Commission File Number) | (I.R.S. Employer |
| of incorporation) |  | Identification No.) |

---

**2121 Williams Street, San Leandro, CA 94577**

(Address of principal executive offices)

**(510) 428-5300**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Not applicable |  |  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 19, 2023 (the "Effective Date"), Nanomix Corporation (the "Company") appointed Chris Hetterly as chief financial officer of the Company, effective immediately. Mr. Hetterly does not have any family relationship with any director, executive officer or person nominated or chosen by us to become an executive officer. There is no understanding or arrangement between Mr. Hetterly and any other person pursuant to which Mr. Hetterly was selected as an executive officer. There are no transactions in which Mr. Hetterly has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Mr. Hetterly succeeds David Ludvigson, who resigned as interim chief financial officer, effective as of the Effective Date. Mr. Ludvigson will continue to serve as corporate secretary of the Company, a member of the Company's board of directors and will serve as a senior business advisor to the Company.

Mr. Hetterly previously served as the Chief Financial Officer of Octagos Health LLC, a healthcare Software-as-a-Service ("Saas") company, from August 2021 to April 2022. He also previously served as the Interim Chief Financial Officer of Weekdays, Inc., a Childcare-as-a-Platform company, from April 2020 until September 2021, and as the Head of Technology Banking for East West Bank, a regional banking company, from July 2017 until December of 2019. Mr. Hetterly received his BA from the Honors Program at Brown University.

On November 15, 2022, the Company entered into an offer letter with Mr. Hetterly. The offer letter has no specific term and constitutes at-will employment. His start date was contingent on the satisfaction of certain conditions. Mr. Hetterly's annual base salary will be $270,000, and he is entitled to a discretionary bonus equal to up to $80,000 based on agreed objectives. The first-year bonus will be paid based on achieving a capital raise of $25 million or more within one year or a change of control. Subsequent years' bonus targets will be adjusted to operating plan metrics as agreed and approved by the Company's board or compensation committee. In connection with his employment, the Company also agreed to grant Mr. Hetterly options to purchase 500,000 shares of common stock (the "Options"), subject to formal approval of the board of directors, which took place on December 13, 2022. The Options shall vest as follows: 12.5% upon the six month anniversary of the date of hire and 1/42 monthly vesting thereafter for remainder of the vesting term. Mr. Hetterly will participate in the compensation and benefit programs generally available to the Company's executive officers.

A copy of the offer letter is attached hereto as Exhibit 10.1 to this Form 8-K and is incorporated herein by reference. The above summary of the offer letter does not purport to be complete and is subject to and qualified in its entirety by reference to the attached agreement.

On January 25, 2023, the Company issued a press release announcing the appointment of Mr. Hetterly. The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. 

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Offer Letter for Chris Hetterly, dated November 15, 2022](ea172154ex10-1_nanomix.htm) |
| 99.1 | [Press Release, dated January 25, 2023](ea172154ex99-1_nanomix.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NANOMIX CORPORATION** | **NANOMIX CORPORATION** |
|  | By: | */s/ Thomas Schlumpberger* |
|  | Name: | Thomas Schlumpberger |
|  | Title: | Chief Executive Officer |
| Date: January 25, 2023 |  |  |

---

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_001.jpg)

November 15, 2022

Christopher R, Hetterly <br> Palo Alto, CA

<u>Via</u> <u>Email</u> - crhetterly@gmail.com

Dear Chris,

We are pleased to offer you the position of **CHIEF FINANCIAL OFFICER** of Nanomix Corporation (the "Company"). As Nanomix Chief Financial Officer, you will be responsible for all financial aspects of the Nanomix business. Your compensation will include a salary of **$270,000** on an annual basis less all applicable deductions and withholdings, paid semi-monthly, and an annual bonus target of $80,000 based on agreed objectives (pro-rated for any partial year of service). If you accept this offer, we expect that you will begin working on or before **December 2, 2022.**

The first-year bonus will be paid based on achieving a capital raise of $25M or more within one year or a change of control transaction. Following years' bonus targets will be adjusted to operating plan metrics as agreed and approved by the Board of Directors Compensation Committee.

On the first day of the month following your start date, you will be eligible to participate in a comprehensive benefits package which includes medical, dental, life and vision insurance, 401(K), 18 days of vacation, 6 sick days, and holidays. Details about these benefit plans will be made available for your review. The Company may modify compensation and benefits from time to time as it deems necessary.

As equity compensation, **subject to approval by the Company's Board of Directors,** you will be granted an option to purchase **500,000** shares of the Company's common stock. The price of such shares shall be the fair market value of the stock at the time of the grant as determined by the Company's Board of Directors. Your option to purchase shares of the Company will be subject to vesting on the following terms: 12.5% shall vest six months after your start date with the balance vesting equally on a monthly basis over the subsequent 42 months subject to the option plan documents. Change of control accelerated vesting shall be in effect for these options as defined in the 2021 EIP Plan documents.

Your employment pursuant to this offer is contingent on your providing the Company with the legally- required proof of your identity and authorization to work in the United States and the completion of a satisfactory Background Check and Reference Check. As a Company employee, you will be expected to abide by Company rules and regulations and sign and comply with the Proprietary Information and Inventions Agreement which, among other things, prohibits the unauthorized use or disclosure of the Company's proprietary information.

2121 Williams St. ● San Leandro, CA 94577 ● 510-428-5300

![](ex10-1_001.jpg)

We hope that your employment with the Company will be satisfying and successful. In order to assure the efficient resolution of any employment-related disputes that may arise between us, we (both you and the Company) agree that any employment-related disputes between us that we are unable to resolve through direct discussion or mediation will be handled through arbitration administered by the American Arbitration Association, pursuant to the Company's Dispute Resolution Program. This agreement to arbitrate is a waiver of the right to file a lawsuit in court and/or the right to have a jury trial.

This letter sets forth the terms of your employment with us and supersedes any prior representations or agreements, whether written or oral. To accept this offer, please sign and return this letter. We will provide the Proprietary Information and Inventions Agreement for you to sign when you begin employment. This offer, if not accepted, will expire on November 21, 2022.

This is the full and complete agreement between us on this term. Although your job duties, title, compensation and benefits, as well as the Company's employment policies and procedures, may change from time-to-time, the "at-will" nature of your employment may only be changed in a document signed by you and the CEO of the Company.

We very much look forward to having you join us.

---

| |
|:---|
| Sincerely, |
| /s/ Thomas Schlumpberger |
| Thomas Schlumpberger |
| CEO |
| Nanomix Corporation |
| ACCEPTANCE: |
| I have read and accept this employment offer. |
| /s/ Christopher R. Hetterly |
| Christopher R. Hetterly |
| Date: 11/15/22 |

---

2121 Williams St. ● San Leandro, CA 94577 ● 510-428-5300

## Exhibit 99.1

**Exhibit 99.1**

**Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer**

**SAN LEANDRO, Calif. (January 25, 2023) – Nanomix Corporation (OTCQB: NNMX) ("Nanomix" or the "Company")**, a leader in mobile, affordable, point-of-care (POC) diagnostics, today announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO).

Mr. Hetterly is a financial executive and entrepreneur, with over 25 years of financial leadership and banking experience. Previously, Mr. Hetterly was the CFO of Octagos Health, a healthcare Software-as-a-Service (SaaS) company. Prior to that, he was a CFO at Madrona Ventures portfolio companies. Mr. Hetterly was the Head of Technology Finance at GE Capital, Wells Fargo, and East West Bank, in addition to being CFO/CIO at Palo Alto Capital. He has raised capital from seed stage to IPO and beyond, and has experience in debt and equity financing, corporate development, business development, with particular expertise in building finance teams and leading in high growth environments. Mr. Hetterly has raised over $10 billion in capital in his career for well-known names such as eBay, Netflix and Symantec amongst others, and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He graduated from Brown University with a BA from the Honors Program.

Thomas Schlumpberger, Nanomix CEO, stated, "We are excited to welcome Chris to the Nanomix management team as our CFO. Chris has more than 25 years in senior financial roles encompassing debt and equity financing, corporate development, and business development. His experience and leadership will be invaluable as we work to establish our technology as a standard of care in POC diagnostics."

**About Nanomix Corporation**

Nanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nanomix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company's products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix's first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit www.nanomixdx.com.

**Forward-Looking Statements**

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

**Investor Relations Contact:**

Natalya Rudman

Crescendo Communications, LLC

Email: NNMX@crescendo-ir.com

Tel: (212) 671-1020 Ext.304

# # #